Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DIAN-TU phase II/III trial of gantenerumab and solanezumab in dominantly inherited Alzheimer's disease
NL-OMON48340Phase 3Withdrawn
- Sponsor
- Washington University in St. Louis
- Start
- Mar 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing Gantenerumab, Solanezumab and Placebo (3 arms). Primary endpoint: Primary efficacy endpoint. Planned start Mar 2019; status: withdrawn.
02
Drugs
gantenerumabsolanezumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON48340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48340.